Urgent.News

What's breaking now, across thousands of outlets.

Business

Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster

EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes

Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

Read the original at qz.com →

More in Business

More from Wednesday 30 September →